NEW YORK--(BUSINESS WIRE)--Gentium S.p.A. (Nasdaq: GENT) announced the publication of the results of an independent clinical study supporting the prophylactic treatment of patients post allogeneic stem cell transplant with Defibrotide as a preventative therapy for veno-occlusive disease, a deadly complication frequent in patients who receive stem cell transplants. Results of the study demonstrated the effectiveness of treatment with Defibrotide in reducing both the incidence of VOD, as well as potentially severe hemorrhagic complications. The data from the Royal Marsden Hospital in the UK were published in the May 14th issue of the journal Bone Marrow Transplantation.
